论文部分内容阅读
Most advanced non-small-cell lung cancer(NSCLC)with activating epidermal growth factor receptor(EGFR)mutations(exon 19 deletions or L858R)initially respond to the EGFR tyrosine kinase inhibitors(TKIs)gefitinib and erlotinib.However,over time(median of 6-12 months),most NSCLC patients developed acquired resistance to EGFR TKIs.